Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

BALTIMORE, May 21 /PRNewswire/ -- Alba Therapeutics Corporation announced today that data from its Phase IIa clinical trial were presented in the Clinical Advances in Celiac Disease session at the Digestive Disease Week (DDW) meeting in San Diego, California. Results of the randomized, double- blind, placebo controlled study of larazotide acetate for the prevention of celiac disease reactivation by gluten challenge in celiac subjects in remission(1) were presented by Daniel Leffler, MD from Beth Israel Deaconess Medical Center at the DDW today.

Celiac disease affects approximately 1% of individuals in the United States and Europe or approximately 6.5 million individuals. The only accepted therapy for the disease is a strict gluten-free diet; however, the response to therapy is poor or incomplete in up to 30% of patients. Dietary non-adherence is the chief cause of persistent or recurrent symptoms(2). Over time, 30-50% of individuals are unable to maintain a strict gluten-free diet. Additionally, a gluten-free diet fails to induce clinical or histological improvement in 7-30% of celiac patients and such a lack of response should trigger a systematic evaluation(3). These facts suggest that there is a need for therapeutic modalities beyond dietary modification.

Alba's study, the first Phase IIa trial in celiac disease and the first to assess dosing requirements for larazotide acetate, was designed to evaluate the safety, tolerability and efficacy of multiple doses of larazotide acetate in celiac disease subjects during a 2 week gluten challenge. The randomized, double-blind, placebo-controlled clinical trial enrolled 86 patients who had a confirmed biopsy diagnosis for celiac disease and were in compliance with a gluten-free diet for at least six months prior to enrollment as demonstrated by a negative serology test of anti-transglutaminase (tTG). Patients were randomized into seven drug-treated and placebo groups and challenged three times a day w
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Mass. , July 10, 2014 Decision ... report awareness of the U.S. Food and Drug Administration,s ... new phosphate binder Velphoro, which was approved by the ... in chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
(Date:1/15/2014)... 15, 2014 Most osteoporosis patients want a choice ... online survey* sponsored by Mission Pharmacal Company. The survey, ... Foundation online support community, revealed that 74 percent of ... in a form other than a pill or a ...
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
Breaking Medicine Technology:Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3
... BIRMINGHAM, Ala., June 8, 2011 SANYO North ... its Cell Processing Work Station (CPWS), an integrated, stand-alone ... stem cell and cell therapies for research use, has ... (UAB) as the nation,s first installation of the CPWS, ...
... 2011 According to a report published today by ... has begun to adapt to stricter governmental brand name ... it files for every new drug. These newer standards ... European Medicines Agency (EMA) are part of an effort ...
Cached Medicine Technology:SANYO Installs First Cell Processing Work Station in the United States at University of Alabama at Birmingham 2SANYO Installs First Cell Processing Work Station in the United States at University of Alabama at Birmingham 3Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands 2Thomson Reuters Trademark Report Reveals New Challenges and Opportunities for Pharmaceutical Brands 3
(Date:7/10/2014)... 10, 2014 In his latest blog ... drug treatment facility CEO Per Wickstrom has listed 5 ... trying to confirm an appointment, get information or sometimes ... following-up without being annoying is a skill that most ... a way to keep the dialogue moving without coming ...
(Date:7/10/2014)... Washington, New York (PRWEB) July 10, 2014 ... firm dedicated to protecting the rights of victims ... couple has brought a lawsuit over allegations that ... her body by a power morcellator used during ... has been filed against Richard Wolf Medical Instruments ...
(Date:7/10/2014)... of electronic health record becomes widespread across the United ... Affordable Care Act, the quantity of clinical data that ... also dramatically increase. Additionally, experts in healthcare have ... quantities of data for the purpose of gleaning insights ... patient care a process that is known as ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Adults with dyslexia are more ... children or teenagers than people who don,t have the ... Dyslexia, which affects up to 10 percent of people, ... 35 percent of adults with this condition said they ... percent of those without dyslexia. "Even after accounting ...
(Date:7/10/2014)... -- Men who have a vasectomy may be at ... suggests. But the risk is comparatively small, the ... study said more research is needed to determine if ... study, Harvard researchers analyzed data from more than 49,400 ... in 1986. During that time, 6,023 cases of prostate ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom’s Latest Blog Post Lists 5 Ways to Follow-up Without Being Annoying 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Six cases where big data can reduce healthcare costs 2Health News:Six cases where big data can reduce healthcare costs 3Health News:Six cases where big data can reduce healthcare costs 4Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 2Health News:Study Links Vasectomy to Aggressive Prostate Cancer 3
... simple magnetic resonance imaging (MRI) test involving breathing oxygen might ... report researchers at UT Southwestern Medical Center. Prior ... a tumor can be a predictor of how well a ... to grow stronger and resist both radiotherapy and chemotherapy. Until ...
... be attributed to the American Chemistry Council (ACC): , ... (ACC) today welcomed a congressional request to the Food and ... evidence on the safety of bisphenol A (BPA) in food-contact ... Henry Waxman and Bart Stupak that an immediate, transparent assessment ...
... dollars in lost productivity annually, according to a ... School of School of Public Health, the International ... South Wales and the African Vision Research Institute. ... suffer with vision impairment resulting from uncorrected refractive ...
... Bus Shelters throughout Washington and Companion TV Spot Highlight CDC,s Failure ... , , HIV Prevalence Rate in Washington ... Lagos , Nigeria , , WASHINGTON, ... through which it highlights the Centers for Disease Control,s (CDC) failure ...
... more than 25 years of experience to support growing ... N.J., June 2 Covance Inc. today announced Monte ... biostatistics for periapproval services. With more than 25 ... and global data management, Jarvis will oversee data management ...
... Medical International Technology Inc. (MDLH.PK) ( http://www.mitcanada.ca ... Mr. Michel Bayouk, our former Corporate Secretary, Principal Accounting ... Michel Bayouk tendered his resignation from Medical International Technology ... officer due to health related reasons. , June 1st ...
Cached Medicine News:Health News:Oxygen + MRI might help determine cancer therapy success, researchers find 2Health News:American Chemistry Council Welcomes Call for Expedited FDA Review of BPA 2Health News:Vision impairment costs billions lost in productivity 2Health News:'AIDS is DC's Katrina' Ad Challenges Obama to Act on U.S. Epidemic 2Health News:'AIDS is DC's Katrina' Ad Challenges Obama to Act on U.S. Epidemic 3Health News:'AIDS is DC's Katrina' Ad Challenges Obama to Act on U.S. Epidemic 4Health News:Covance Announces Monte Jarvis as Vice President of Global Data Management and Biostatistics for Periapproval Services 2Health News:Covance Announces Monte Jarvis as Vice President of Global Data Management and Biostatistics for Periapproval Services 3Health News:Mr. Michel Bayouk resignation and passing 2
Contrast sensitivity testing, glare sensitivity testing and ETDRS acuity testing are provided in the self standardized CSV-1000 instrument. Patented photocell circuitry automatically monitors and cal...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... Reviews enable all those involved with healthcare ... the very latest evidence in their field ... harder each year as the volume of ... by delivering the best single source available ...
Muscles Anatomy Flash Cards uses the time tested content and images from BryanEdwards.com....
Medicine Products: